Replies to post #43333 on Sunshine Biopharma Inc (SBFM)

[EOT]

Lol, only heard that hundreds of times.


They have positioned the company for impressive growth.
Post r/s....... uplist to QB.
2019 is the year that Adva-27a will shock the world $$


SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL 9TM, THE COMPANY'S FIRST OVER THE COUNTER ESSENTIAL MICRONUTRIENT

MONTREAL, CANADA / ACCESSWIRE / December 17, 2018 / Sunshine Biopharma, Inc. (OTC PINK: "SBFM") today announced that it has received Health Canada approval for Essential 9TM, the first in a line of essential micronutrients products that the Company is planning to launch. On Friday December 14, 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM are dietary supplement tablets that contain a balanced formula of the 9 essential amino acids that the human body cannot make. Sunshine Biopharma anticipates to start shipping Essential 9TM in the second week of January 2019.

About Essential 9TM

Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma's Essential 9TM provides all 9 Essential Amino Acids in free form and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.





SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF ADVA-27A ANTICANCER DRUG

MONTREAL, QC / ACCESSWIRE / December 12, 2018 / Sunshine Biopharma, Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has signed an agreement with Crocus Laboratories Inc. (Crocus), a Montreal based company for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a, Sunshine's lead anticancer compound targeted for Pancreatic Cancer. The material which will ultimately be generated by a contract manufacturing organization will be used for animal toxicity studies and clinical trials.



About Crocus Laboratories Inc.

Crocus Laboratories Inc. is a Canadian medicinal chemistry company engaged in the design and synthesis of new chemical entities, including enzyme inhibitors, receptor modulators and compound libraries. The Crocus team has extensive experience in drug discovery and development, particularly in the areas of oncology and infectious diseases. More information about Crocus is available at www.crocuslaboratories.com.

About Sunshine Biopharma's Adva-27a

Adva-27a is Sunshine Biopharma's proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug's effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.